Venous thromboembolism in hematopoietic stem cell transplant recipients.

Chaturvedi S, Neff A, Nagler A, Savani U, Mohty M, Savani BN
Bone Marrow Transplant. 2016 51 (4): 473-8

PMID: 26691425 · DOI:10.1038/bmt.2015.308

Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.

MeSH Terms (9)

Allografts Graft vs Host Disease Hematopoietic Stem Cell Transplantation Humans Lenalidomide Multiple Myeloma Postoperative Complications Thalidomide Venous Thromboembolism

Connections (1)

This publication is referenced by other Labnodes entities: